Switch theme
Sign up to access all valuation multiples
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
1996
n/a
LTM Revenue $445M
LTM EBITDA $168M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amoytop Biotech has a last 12-month revenue (LTM) of $445M and a last 12-month EBITDA of $168M.
In the most recent fiscal year, Amoytop Biotech achieved revenue of $391M and an EBITDA of $140M.
Amoytop Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amoytop Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $445M | XXX | $391M | XXX | XXX | XXX |
| Gross Profit | $417M | XXX | $366M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $168M | XXX | $140M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $155M | XXX | $134M | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| Net Profit | $131M | XXX | $115M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Amoytop Biotech's stock price is CNY 77 (or $11).
Amoytop Biotech has current market cap of CNY 31.4B (or $4.4B), and EV of CNY 30.6B (or $4.3B).
See Amoytop Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $4.4B | XXX | XXX | XXX | XXX | $0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Amoytop Biotech has market cap of $4.4B and EV of $4.3B.
Amoytop Biotech's trades at 10.9x EV/Revenue multiple, and 30.4x EV/EBITDA.
Equity research analysts estimate Amoytop Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amoytop Biotech has a P/E ratio of 33.3x.
See valuation multiples for Amoytop Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 9.6x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBITDA | 25.3x | XXX | 30.4x | XXX | XXX | XXX |
| EV/EBIT | 27.5x | XXX | 31.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.3x | XXX | 38.0x | XXX | XXX | XXX |
| EV/FCF | 56.0x | XXX | 170.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmoytop Biotech's last 12 month revenue growth is 32%
Amoytop Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Amoytop Biotech's rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amoytop Biotech's rule of X is 117% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amoytop Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | 43% | XXX | XXX | XXX |
| Rule of 40 | 65% | XXX | 68% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 117% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amoytop Biotech acquired XXX companies to date.
Last acquisition by Amoytop Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Amoytop Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amoytop Biotech founded? | Amoytop Biotech was founded in 1996. |
| Where is Amoytop Biotech headquartered? | Amoytop Biotech is headquartered in China. |
| Is Amoytop Biotech publicy listed? | Yes, Amoytop Biotech is a public company listed on SHG. |
| What is the stock symbol of Amoytop Biotech? | Amoytop Biotech trades under 688278 ticker. |
| When did Amoytop Biotech go public? | Amoytop Biotech went public in 2020. |
| Who are competitors of Amoytop Biotech? | Similar companies to Amoytop Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amoytop Biotech? | Amoytop Biotech's current market cap is $4.4B |
| What is the current revenue of Amoytop Biotech? | Amoytop Biotech's last 12 months revenue is $445M. |
| What is the current revenue growth of Amoytop Biotech? | Amoytop Biotech revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Amoytop Biotech? | Current revenue multiple of Amoytop Biotech is 9.6x. |
| Is Amoytop Biotech profitable? | Yes, Amoytop Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amoytop Biotech? | Amoytop Biotech's last 12 months EBITDA is $168M. |
| What is Amoytop Biotech's EBITDA margin? | Amoytop Biotech's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Amoytop Biotech? | Current EBITDA multiple of Amoytop Biotech is 25.3x. |
| What is the current FCF of Amoytop Biotech? | Amoytop Biotech's last 12 months FCF is $75.9M. |
| What is Amoytop Biotech's FCF margin? | Amoytop Biotech's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Amoytop Biotech? | Current FCF multiple of Amoytop Biotech is 56.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
